Menu Search
Equities

NKGen Biotech Inc

NKGN:NMQ

NKGen Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3375
  • Today's Change0.025 / 7.83%
  • Shares traded3.81m
  • 1 Year change-87.83%
  • Beta0.5750
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year NKGen Biotech Inc's revenues fell -100.00% from 77.00k to 0.00. has fallen 210.06% from a loss of 26.75m to a larger loss of 82.95m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-480.25%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, NKGen Biotech Inc increased its cash reserves by 135.90%, or 159.00k. Cash Flow from Financing totalled 22.16m or -- of revenues. In addition the company used 21.95m for operations while cash used for investing totalled 48.00k.
Cash flow per share-3.72
Price/Cash flow per share--
Book value per share-2.71
Tangible book value per share-2.71
More ▼

Balance sheet in USDView more

NKGen Biotech Inc uses little or no debt in its capital structure.
Current ratio0.0243
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.